Nanotechnology for Cancer Vaccines
A Special Issue of Vaccines (ISSN 2076-393X) belonging to the section "Vaccination Against Cancer and Chronic Diseases".
Deadline for manuscript submissions: 31 December 2026 | Viewed by 2260
Editor
Interests: cancer immunotherapy; nanotechnology; cancer vaccine; adjuvant; in situ cancer vaccine; cancer combination therapy; nanoparticle; immune checkpoint inhibitor
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue will focus on the innovative use of nanotechnology in the development of cancer vaccines. It will highlight research on nanoparticle-based delivery systems, nanoformulations of tumor antigens and adjuvants, and strategies to enhance immune responses against cancer. This issue seeks contributions that explore targeted and personalized nanovaccines, preclinical and clinical studies, and novel design approaches to improving vaccine efficacy, safety, and stability. By bringing together advances in nanotechnology and cancer immunotherapy, this Special Issue aims to provide insights into the next generation of effective cancer vaccines.
Dr. Xiupeng Wang
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanotechnology
- cancer vaccines
- nanoparticle
- tumor antigens
- vaccine adjuvants
- immune therapeutics
- inhibitory receptors
- immune response modulation
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
